指南与共识心力衰竭与心肌病

指南导向药物治疗在心力衰竭中的全球最佳实施影响

Global Impact of Optimal Implementation of Guideline-Directed Medical Therapy in Heart Failure.
指南 / 共识 · JAMA Cardiol · 2024-01-01

该研究基于已发表数据估算全球射血分数降低的心力衰竭(HFrEF)患者中指南导向药物治疗(GDMT)的使用缺口,并计算最佳实施四联疗法可避免的12个月全因死亡数。

要点

  • 全球HFrEF患者中GDMT使用不足,存在显著治疗差距。
  • 死亡避免数在东南亚、东地中海、非洲和西太平洋地区占比较大。

核心结论

  • 改善GDMT使用可在全球范围内带来显著的死亡率获益,但各地区间存在显著异质性,需针对国家差异制定干预措施以优化GDMT worldwide。

研究设计与样本

  • 基于已发表来源估算HFrEF患病率、GDMT禁忌证、治疗率和12个月全因死亡需治疗人数,计算全球最佳实施四联疗法可能挽救的生命数,并进行敏感性分析以考虑现有数据的不确定性。

主要发现

  • 避免的死亡中很大比例预计在东南亚、东地中海和非洲以及西太平洋地区。

临床怎么用

  • 应致力于缩小GDMT在全球范围内的使用差距,以最大程度降低HFrEF患者死亡率。
  • 需根据地区差异制定针对性干预措施以优化GDMT实施。

局限性

  • 数据来源于已发表来源,存在不确定性,已通过敏感性分析考虑。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Guideline-directed medical therapy (GDMT) remains underutilized on a global level, with significant disparities in access to treatment worldwide. The potential global benefits of quadruple therapy on patients with heart failure with reduced ejection fraction (HFrEF) have not yet been estimated. OBJECTIVE: To assess the projected population-level benefit of optimal GDMT use globally among patients with HFrEF. DESIGN, SETTING, AND PARTICIPANTS: Estimates for HFrEF prevalence, contraindications to GDMT, treatment rates, and the number needed to treat for all-cause mortality at 12 months were derived from previously published sources. Potential lives saved from optimal implementation of quadruple therapy among patients with HFrEF was calculated globally and a sensitivity analysis was conducted to account for uncertainty in the existing data. MAIN OUTCOMES AND MEASURES: All-cause mortality. RESULTS: Of an estimated 28.89 million people with HFrEF worldwide, there were 8 235 063 (95% CI, 6 296 020-10 762 972) potentially eligible for but not receiving β-blockers, 20 387 000 (95% CI, 15 867 004-26 184 996) eligible for but not receiving angiotensin receptor-neprilysin inhibitors, 12 223 700 (95% CI, 9 376 895-15 924 973) eligible for but not receiving mineralocorticoid receptor antagonists, and 21 229 170 (95% CI, 16 537 400-27 242 688) eligible for but not receiving sodium glucose cotransporter-2 inhibitors. Optimal implementation of quadruple GDMT could potentially prevent 1 188 277 (95% CI, 767 933-1 914 561) deaths over 12 months. A large proportion of deaths averted were projected in Southeast Asia, Eastern Mediterranean and Africa, and the Western Pacific regions. CONCLUSIONS AND RELEVANCE: Improvement in use of GDMT could result in substantial mortality benefits on a global scale. Significant heterogeneity also exists across regions, which warrants additional study with interventions tailored to country-level differences for optimization of GDMT worldwide.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Tang AB, Ziaeian B, Butler J, et al. Global Impact of Optimal Implementation of Guideline-Directed Medical Therapy in Heart Failure. JAMA Cardiol. 2024. PMID: 39356517. doi:10.1001/jamacardio.2024.3023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。